Cost effectiveness and cost utility of acetylcysteine versus dimethyl sulfoxide for reflex sympathetic dystrophy

PharmacoEconomics

Volumn 21, Issue 2, 2003, Pages 139-148

  Van Dieten, Hiske E M ^a,b   Perez, Roberto S G M ^b   Van Tulder, Maurits W ^a   De Lange, Jaap J ^b   Zuurmond, Wouter W A ^b   Ader, Herman J ^a   Vondeling, Hindrik ^c   Boers, Maarten ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; DIMETHYL SULFOXIDE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACETYLCYSTEINE; COST-BENEFIT ANALYSIS; DATA COLLECTION; DIMETHYL SULFOXIDE; DOUBLE-BLIND METHOD; DRUG COSTS; FEMALE; FREE RADICAL SCAVENGERS; HOSPITAL COSTS; HOSPITALS, UNIVERSITY; HUMANS; MALE; NETHERLANDS; REFLEX SYMPATHETIC DYSTROPHY; TREATMENT OUTCOME;

EID: 0037239303     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321020-00006     Document Type: Article

References (28)

1. Rowlingson JC. The sympathetic dystrophies. Int Anesthesiol Clin 1983; 21: 117-29
2. Zuurmond WWA, Langendijk PNJ, Bezemer PB, et al. Treatment of acute reflex sympathetic dystrophy with DMSO 50% in a fatty cream. Acta Anaesthesiol Scand 1996; 40: 364-7
3. Veldman PHJM, Goris RJA. Multiple reflex sympathetic dystrophy: which patients are at risk for developing a recurrence of reflex sympathetic dystrophy in the same or another limb. Pain 1996; 64: 463-6
4. Jadad AR, Carroll D, Glynn CJ. Intravenous regional sympathetic blockade for pain relief in reflex sympathetic dystrophy: a systematic review and a randomized, double-blind crossover study. J Pain Symptom Manage 1995; 10: 13-20
5. Oerlemans HM, Oostendorp RA, de Boo T. Adjuvant physical therapy versus occupational therapy in patients with reflex sympathetic dystrophy/complex regional pain syndrome type I. Arch Phys Med Rehabil 2000 Jan; 81: 49-56
6. Goris RJA. Treatment of reflex sympathetic dystrophy with hydroxyl radical scavengers. Unfallchirurg 1985; 88: 330-2
7. Veldman PHJM, Reynen JAM, Arntz IE. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet 1993; 342: 1012-6
8. Oerlemans HM, Goris RJ, Oostendorp RA. Impairment level sumscore in reflex sympathetic dystrophy of one upper extremity. Arch Phys Med Rehabil 1998 Aug; 79 (8): 979-90
9. Goossens ME, Rutten-van Molken MP, Vlaeyen JW, et al. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol 2000 Jul; 53 (7): 688-95
10. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek. Apeldoorn: VDA groep, 2000: 1-178
11. Taxe report. The Hague: Royal Dutch Association for the Advancement of Pharmacy, 1999
12. Taxe report: over the counter drugs. The Hague: Royal Dutch Association for the advancement of Pharmacy, 1999
13. Severens JL, Oerlemans HM, Weegels AJPG. Cost-effectiveness analysis of adjuvant physical therapy or occupational therapy for patients with reflex sympathetic dystrophy. Arch Phys Med Rehabil 1999; 80: 1038-43
14. Koopmanschap MA, Rutten FF. The consequence of production loss or increased costs of production. Med Care 1996 Dec; 34 (12 Suppl.): DS59-68
15. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997 Jul-Aug; 6 (4): 327-40
16. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall, 1993
17. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001 Mar; 10 (2): 179-84
18. Briggs A, Fenn P. Confidence intervals or surfaces?: uncertainty on the cost-effectiveness plane. Health Econ 1998 Dec; 7 (8): 723-40
19. Drummond MF, O'Brien B, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: University Press, 1999: 68-74
20. Yu ZW, Quinn PJ. Dimethyl sulphoxide: a review of its applications in cell biology. Biosci Rep 1994 Dec; 14 (6): 259-81
21. Al MJ, van Hout BA, Michel BC, et al. Sample size calculation in economic evaluations. Health Econ 1998 Jun; 7 (4): 327-35
22. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000; 320: 1197-200
23. Desagné A, Castilloux A, Angers J, et al. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998; 13 (5): 487-97
24. Sacristan JA, Obenchain RL. Reporting cost-effectiveness analyses with confidence. JAMA 1997 Feb 5; 277 (5): 375
25. Stinnett AA, Paltiel AD. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making 1997 Oct-Dec; 17 (4): 483-9
26. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998 Apr-Jun; 18 (2 Suppl.): S68-80
27. Perez RSGM, Kwakkel G, Zuurmond WA, et al. Medicinal treatment of reflex sympathetic dystrophy (CRPS type 1): a research synthesis of 21 randomised clinical trials. J Pain Symptom Manag 2001b; 21: 511-26
28. Kemler MA, Furnée CA. Economic evaluation of spinal cord stimulation for chronic reflex sympathetic dystrophy. Thesis: spinal cord stimulation for chronic reflex sympathetic dystrophy. Maastricht, The Netherlands: University of Maastricht, 2000: 93-106